TY  - JOUR
AU  - Kong, Anthony
AU  - Rea, Daniel
AU  - Ahmed, Samreen
AU  - Beck, J Thaddeus
AU  - López López, Rafael
AU  - Biganzoli, Laura
AU  - Armstrong, Anne C
AU  - Aglietta, Massimo
AU  - Alba, Emilio
AU  - Campone, Mario
AU  - Hsu Schmitz, Shu-Fang
AU  - Lefebvre, Caroline
AU  - Akimov, Mikhail
AU  - Lee, Soo-Chin
PY  - 2016
DO  - 10.18632/oncotarget.8974
UR  - http://hdl.handle.net/10668/10039
T2  - Oncotarget
AB  - This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a...
LA  - en
KW  - AUY922
KW  - HER2
KW  - HSP90 inhibitor
KW  - breast cancer
KW  - trastuzumab
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bayes Theorem
KW  - Breast Neoplasms
KW  - Cohort Studies
KW  - Disease Progression
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - HSP90 Heat-Shock Proteins
KW  - Humans
KW  - Isoxazoles
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Receptor, ErbB-2
KW  - Resorcinols
KW  - Trastuzumab
KW  - Treatment Outcome
TI  - Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
TY  - research article
VL  - 7
ER  -